We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · September 22, 2022

ESMO 2022: Overall Survival Increased for Non-Small Cell Lung Cancer Patients Using Atezolizumab

Atezolizumab may offer robust treatment option in patients with non-small cell lung cancer intolerant to platinum-based chemotherapy

PracticeUpdate Editorial Team


Further Reading